We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Keytruda Approved for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma
Keytruda Approved for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma
The FDA has approved Merck’s Keytruda (pembrolizumab) for patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation.